Abbott Laboratories stock heads into the open after a 0.7 percent gain
📈 Abbott Laboratories stock closed at USD 102.61 on September 21, 2026, marking a 0.7 percent gain for the session.
📊 The shares have appreciated 14.1 percent over the last three months, rising from a price of USD 89.90 to the current level.
💰 Abbott confirmed a quarterly dividend of USD 0.63 per share with an ex-dividend date leading to payment on November 16, 2026.
⚖️ The company agreed to a USD 385 million civil settlement regarding allegations of contaminated infant formula from its Sturgis and Casa Grande plants.
🏭 Legal developments involving the infant formula contamination remain a primary focus for investors analyzing Abbott's September 22 trading session.
Bullish Signals
- Abbott Laboratories stock gained 0.7 percent to close at USD 102.61 on September 21, 2026, demonstrating resilience despite broader market volatility.
- The company's shares have rallied 14.1 percent over the past three months, indicating sustained investor interest and positive momentum in the stock price.
Risk Factors
- Abbott Laboratories agreed to a USD 385 million civil settlement regarding contaminated infant formula allegations, representing a significant immediate financial liability.
- The company faces ongoing legal exposure and reputational risk linked to contamination issues at its Sturgis and Casa Grande manufacturing facilities.
Full Analysis
Abbott Laboratories stock opened on September 22, 2026, following a close price of USD 102.61 on the NYSE on September 21, 2026. The shares gained 0.7 percent for the session and were up 14.1 percent over the preceding three months from a low of USD 89.90. While the broader S&P 500 index rose 1.4 percent on the same date, Abbott's performance reflected specific market dynamics rather than broad index outperformance.
Key financial and legal developments continue to define the company's immediate outlook. The firm has confirmed a quarterly dividend of USD 0.63 per share, payable to shareholders on November 16, 2026. Simultaneously, Abbott agreed to a significant civil settlement totaling USD 385 million related to allegations concerning contaminated infant formula produced at its facilities in Sturgis and Casa Grande.
The company faces ongoing scrutiny regarding the legal exposure associated with the infant formula contamination allegations. This settlement represents a material cash outflow that impacts the company's liquidity and earnings for the period. Investors are monitoring how this specific liability, combined with the dividend payout schedule, influences Abbott's balance sheet and future operational flexibility in the coming quarters.
